JP2022519293A5 - - Google Patents
Info
- Publication number
- JP2022519293A5 JP2022519293A5 JP2021545713A JP2021545713A JP2022519293A5 JP 2022519293 A5 JP2022519293 A5 JP 2022519293A5 JP 2021545713 A JP2021545713 A JP 2021545713A JP 2021545713 A JP2021545713 A JP 2021545713A JP 2022519293 A5 JP2022519293 A5 JP 2022519293A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fragment
- seq
- opening
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025036066A JP2025090679A (ja) | 2019-02-04 | 2025-03-07 | コネキシン４３抗体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962800869P | 2019-02-04 | 2019-02-04 | |
| US62/800,869 | 2019-02-04 | ||
| PCT/US2020/016606 WO2020163353A1 (en) | 2019-02-04 | 2020-02-04 | Connexin 43 antibodies and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025036066A Division JP2025090679A (ja) | 2019-02-04 | 2025-03-07 | コネキシン４３抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022519293A JP2022519293A (ja) | 2022-03-22 |
| JP2022519293A5 true JP2022519293A5 (enExample) | 2023-02-13 |
| JP7709917B2 JP7709917B2 (ja) | 2025-07-17 |
Family
ID=71947290
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021545713A Active JP7709917B2 (ja) | 2019-02-04 | 2020-02-04 | コネキシン４３抗体およびその使用 |
| JP2025036066A Pending JP2025090679A (ja) | 2019-02-04 | 2025-03-07 | コネキシン４３抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025036066A Pending JP2025090679A (ja) | 2019-02-04 | 2025-03-07 | コネキシン４３抗体およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12187794B2 (enExample) |
| EP (1) | EP3920969A4 (enExample) |
| JP (2) | JP7709917B2 (enExample) |
| KR (1) | KR20210153039A (enExample) |
| CN (2) | CN119700967A (enExample) |
| AU (3) | AU2020219112A1 (enExample) |
| CA (1) | CA3128987A1 (enExample) |
| IL (2) | IL320816A (enExample) |
| WO (1) | WO2020163353A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12227561B2 (en) | 2018-04-02 | 2025-02-18 | Alamab Therapeutics, Inc. | Connexin 43 antibodies and use thereof |
| CA3190474A1 (en) * | 2020-07-31 | 2022-02-03 | Alamab Therapeutics, Inc. | Anti-connexin antibody formulations |
| WO2025006774A1 (en) * | 2023-06-30 | 2025-01-02 | Alamab Therapeutics, Inc. | Method of treating osteoarthritis |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| WO2003057881A1 (en) * | 2001-12-28 | 2003-07-17 | Chugai Seiyaku Kabushiki Kaisha | Method of stabilizing protein |
| US6745478B2 (en) | 2002-07-18 | 2004-06-08 | Delillo Dominick D. | Multi-purpose work knife |
| ES2399050T3 (es) * | 2003-12-10 | 2013-03-25 | Medarex, Inc. | Anticuerpos contra interferón alfa y sus usos |
| EP2662088A3 (en) | 2005-02-03 | 2014-02-19 | Coda Therapeutics Limited | Anti-connexin compounds and uses thereof |
| JP2011523414A (ja) * | 2008-05-15 | 2011-08-11 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 抗ｆｎ１４抗体、およびその使用 |
| JP2011524345A (ja) | 2008-06-04 | 2011-09-01 | コーダ セラピューティクス， インコーポレイテッド | ギャップジャンクション調節化合物を用いる疼痛の治療 |
| CA2823154A1 (en) | 2010-12-27 | 2012-07-05 | Lsip, Llc | Ips cells and method for generating same |
| CN114621346B (zh) * | 2013-08-21 | 2025-06-10 | 德克萨斯州大学系统董事会 | 用于靶向连接蛋白半通道的组合物和方法 |
| US9493552B2 (en) | 2013-11-15 | 2016-11-15 | China Synthetic Rubber Corporation | Therapeutic biologic for treatment of hepatocellular carcinoma |
| JP6683686B2 (ja) | 2014-08-22 | 2020-04-22 | オークランド ユニサービシーズ リミティド | チャネル調節剤 |
| WO2017024465A1 (en) * | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| EP3419998A4 (en) * | 2016-02-26 | 2019-09-25 | The Board of Regents of The University of Texas System | CONNEXIN (CX) 43 HEMICANAL BINDING ANTIBODIES AND USES THEREOF |
| US12227561B2 (en) | 2018-04-02 | 2025-02-18 | Alamab Therapeutics, Inc. | Connexin 43 antibodies and use thereof |
| CA3190474A1 (en) * | 2020-07-31 | 2022-02-03 | Alamab Therapeutics, Inc. | Anti-connexin antibody formulations |
-
2020
- 2020-02-04 CA CA3128987A patent/CA3128987A1/en active Pending
- 2020-02-04 IL IL320816A patent/IL320816A/en unknown
- 2020-02-04 WO PCT/US2020/016606 patent/WO2020163353A1/en not_active Ceased
- 2020-02-04 KR KR1020217027864A patent/KR20210153039A/ko active Pending
- 2020-02-04 CN CN202411949862.9A patent/CN119700967A/zh active Pending
- 2020-02-04 US US17/767,171 patent/US12187794B2/en active Active
- 2020-02-04 CN CN202080002561.9A patent/CN112384244B/zh active Active
- 2020-02-04 AU AU2020219112A patent/AU2020219112A1/en not_active Abandoned
- 2020-02-04 EP EP20752507.2A patent/EP3920969A4/en active Pending
- 2020-02-04 JP JP2021545713A patent/JP7709917B2/ja active Active
- 2020-02-04 IL IL285369A patent/IL285369B2/en unknown
-
2022
- 2022-08-18 AU AU2022218583A patent/AU2022218583B9/en active Active
-
2024
- 2024-11-21 US US18/955,222 patent/US20250230233A1/en active Pending
-
2025
- 2025-03-07 JP JP2025036066A patent/JP2025090679A/ja active Pending
-
2026
- 2026-02-20 AU AU2026201299A patent/AU2026201299A1/en active Pending